Reata Pharmaceuticals, Inc. to Report Third Quarter 2020 Financial Results and Provide an Update on Development Programs on November 9, 2020

Rhea-AI Summary

Reata Pharmaceuticals (Nasdaq: RETA) will report its Q3 2020 financial results and development program updates on November 9, 2020, before market opening. A conference call is scheduled for 8:00 a.m. ET, accessible via toll-free and international numbers. The earnings press release will be available prior to the call on the company's website. Reata develops innovative therapies targeting critical molecular pathways for serious diseases, with two leading candidates, bardoxolone methyl and omaveloxolone, currently under investigation.

Positive

• Reata is advancing its drug development, focusing on bardoxolone methyl and omaveloxolone.
• The upcoming earnings call indicates transparency and engagement with investors.

Negative

• Bardoxolone and omaveloxolone are still under investigation, indicating uncertainty regarding their safety and efficacy.
• -

PLANO, Texas, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on its development programs before the market opens on November 9, 2020.

Reata’s management will host a conference call on November 9, 2020 at 8:00 a.m. ET. The conference call will be accessible by dialing (844)348-3946 (toll-free domestic) or (213)358-0892 (international) using the access code: 2896858. The webcast link is https://edge.media-server.com/mmc/p/z6fgbcwf.

Third quarter 2020 financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at http://reatapharma.com/investors/ and will be available for 12 months after the call. The audio recording and webcast will be accessible for at least 90 days after the event at http://reatapharma.com/investors/.

About Reata Pharmaceuticals, Inc.

Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl (“bardoxolone”) and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling. Bardoxolone and omaveloxolone are investigational drugs, and their safety and efficacy have not been established by any agency.

Contact:
Reata Pharmaceuticals, Inc.
(972) 865-2219
http://reatapharma.com

Investors:
Vinny Jindal
Vice President, Investor Relations and Corporate Communications
(469) 374-8721
ir@reatapharma.com
http://reatapharma.com/contact-us/

FAQ

When will Reata Pharmaceuticals report Q3 2020 earnings?

Reata Pharmaceuticals will report Q3 2020 earnings on November 9, 2020.

What time is the Reata Pharmaceuticals conference call?

The conference call will be held at 8:00 a.m. ET on November 9, 2020.

Where can I find the Reata Pharmaceuticals Q3 2020 earnings press release?

The earnings press release will be available on Reata's website shortly before the conference call.

What are Reata Pharmaceuticals' main drug candidates?

Reata's main drug candidates are bardoxolone methyl and omaveloxolone, both targeting Nrf2.

How can I access the Reata Pharmaceuticals conference call?

The conference call can be accessed by dialing (844) 348-3946 for domestic or (213) 358-0892 for international calls.